Hyponatraemia in heart failure

Su Ling Tee; Andrew Sindone; Simon Roger; John Atherton; John Amerena; Michael D'Emden; Jonathan Erlich; Carmine De Pasquale

doi:10.1111/imj.14624

Hyponatraemia in heart failure

Intern Med J. 2020 Jun;50(6):659-666. doi: 10.1111/imj.14624.

Authors

Su Ling Tee¹, Andrew Sindone², Simon Roger³, John Atherton⁴, John Amerena⁵, Michael D'Emden⁶, Jonathan Erlich⁷, Carmine De Pasquale⁸

Affiliations

¹ Department of Cardiology, The Alfred, Melbourne, Victoria, Australia.
² Heart Failure Unit and Department of Cardiac Rehabilitation, Concord Hospital, Sydney, New South Wales, Australia.
³ Department of Renal Medicine, Gosford Hospital, Gosford, New South Wales, Australia.
⁴ Department of Cardiology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁵ Department of Cardiology Research, Barwon Health, Brisbane, Victoria, Australia.
⁶ Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
⁷ Department of Renal Medicine, Prince of Wales Hospital, Randwick, New South Wales, Australia.
⁸ Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia.

PMID: 31449715
DOI: 10.1111/imj.14624

Abstract

Hyponatraemia is common in heart failure (HF). It is estimated that over 20% of patients admitted to hospital with HF have hyponatraemia. It has also been repeatedly shown to be a surrogate marker of increased morbidity and mortality in this specific population. This review focuses on the pathophysiology of hyponatraemia through the activation of neurohormonal cascades in HF, the clinical implications of sustained hyponatraemia and treatment options in the management of this challenging phenomenon.

Keywords: acute heart failure; chronic heart failure; hyponatraemia.

Publication types

Review

MeSH terms

Biomarkers
Heart Failure* / diagnosis
Hospitalization
Humans
Hyponatremia* / diagnosis
Hyponatremia* / epidemiology
Hyponatremia* / therapy
Prognosis

Substances

Biomarkers